About the Authors

Rikio Suzuki

Contributed equally to this work with: Rikio Suzuki, Shohei Kikuchi, Takeshi Harada

Affiliations Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America, Department of Hematology/Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan

Shohei Kikuchi

Contributed equally to this work with: Rikio Suzuki, Shohei Kikuchi, Takeshi Harada

Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

Takeshi Harada

Contributed equally to this work with: Rikio Suzuki, Shohei Kikuchi, Takeshi Harada

Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

Naoya Mimura

Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

Jiro Minami

Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

Hiroto Ohguchi

Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

Yasuhiro Yoshida

Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

Morihiko Sagawa

Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

Gullu Gorgun

Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

Diana Cirstea

Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

Francesca Cottini

Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

Jana Jakubikova

Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

Yu-Tzu Tai

Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

Dharminder Chauhan

Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

Paul G. Richardson

Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

Nikhil Munshi

Affiliation VA Boston Healthcare System, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

Kiyoshi Ando

Affiliation Department of Hematology/Oncology, Tokai University School of Medicine, Isehara, Kanagawa, Japan

Teruhiro Utsugi

Affiliation Tsukuba Research Center, Taiho Pharmaceutical Co., Ltd., Tsukuba, Japan

Teru Hideshima

Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

Kenneth C. Anderson

kenneth_anderson@dfci.harvard.edu

Affiliation Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America

Competing Interests

The authors of this manuscript have the following competing interests: T.U. is an employee at Taiho Pharmaceutical Co., Ltd. Y.-T.T. is a consultant for Onyx. D.C. is a consultant for Oncopeptides AB. P.G.R. is a member of the advisory boards for Celgene, Millennium, Johnson & Johnson, Novartis, and Bristol-Myers Squibb. N.M. is a member of the advisory boards for Millennium, Celgene, and Novartis. T.H. is a consultant for Acetylon Pharmaceuticals. K.C.A. is a member of the advisory boards for Onyx, Celgene, Gilead, and Sanofi-Aventis, and is a scientific founder of Acetylon and Oncopep. J.M. receives research funding from Bristol-Myers Squibb. The other authors declare no conflicts of interest. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: RS SK T. Harada D. Cirstea JJ YTT D. Chauhan KA TU T. Hideshima KCA. Performed the experiments: RS SK T. Harada N. Mimura JM HO YY MS GG FC T. Hideshima. Analyzed the data: RS SK T. Harada D. Chauhan PGR N. Munshi T. Hideshima KCA. Wrote the paper: RS SK T. Harada T. Hideshima KCA.